IP Library Granted Patent US 9,345,705
Granted Patent B2
US 9,345,705 · App. 14/344,190 · Granted May 24, 2016

Compositions and methods for treating cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,705
App. No.
14/344,190
Granted
May 24, 2016
Kind
B2
Abstract

The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is MK-1775 or a pharmaceutically acceptable salt thereof, or MK-3652 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is MK-8776 or a pharmaceutically acceptable salt thereof, or SCH900444 or a pharmaceutically acceptable salt thereof.

Claims (7)

1. A method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer, and ovarian cancer, with a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is MK-1775 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is MK-8776 or a pharmaceutically acceptable salt thereof.

2. A method of claim 1 for treating a cancer patient, in need of treatment thereof, comprising administering to said patient a therapeutically effective amount of said WEE1 inhibitor and said CHK1 inhibitor.

3. The method of claim 2 wherein the WEE1 inhibitor is administered in a dose between 100 mg per day and 250 mg per day.

4. The method of claim 3 wherein the WEE1 inhibitor is administered five times, over the course of two and a half days.

5. The method of claim 3 wherein the WEE1 inhibitor is administered once a day, over the course of two days.

6. The method of claim 2 wherein the CHK1 inhibitor is administered in a dose between 100 mg per day and 200 mg per day.

7. The method of claim 6 wherein the CHK1 inhibitor is administered once a day, over the course of two days.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2014
From: SHUMWAY, STUART DENHAM; TONIATTI, CARLO; ROBERTS, BRIAN SCOTT; MARTIN, MELISSA M.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032412/0338 →